In April, CNN ran a piece titled "Peptides: what's real, what's risky and what's next." Eric Topol followed with "The Peptide Craze" on Ground Truths. Both are worth reading. Both are correct that the marketing has outrun the data. Neither is the final word on whether the molecules work — and neither addresses the question a thoughtful patient is actually asking, which is: given honest uncertainty, what is a reasonable physician's posture?
This is that posture. Where the evidence is robust, we say so. Where it is thin, we say that too. And where Limitless prescribes inside thin evidence, we explain how the prescribing is structured to be defensible.
The landscape, in one paragraph.
A January 2026 review in Frontiers in Aging catalogued nine peptides with at least preliminary support in gerontology: tirzepatide (metabolic restoration), epitalon (telomere biology), GHK-Cu (dermal regeneration), BPC-157 and TB-500 (tissue repair), Semax (neuroprotection), CJC-1295 and ipamorelin (growth hormone modulation), and bremelanotide (sexual function). The review is the clearest single statement available of where the field stands. None of these are panaceas. Several of them are useful in defined indications. The intellectually honest task is sorting which is which.
Three tiers of evidence.
The peptides on the Limitless menu fall into three categories. We are explicit about the category each falls in.
| Peptide | Evidence tier | Limitless posture |
|---|---|---|
| Tesamorelin | FDA-approved (HIV lipodystrophy). 2026 pooled meta-analysis: −27.7 cm² VAT, +1.42 kg lean mass. | Standard 2 mg SubQ nightly for indicated patients. |
| Tadalafil (daily 5 mg) | FDA-approved (BPH, ED). Mechanistic literature for endothelial, CV, cognitive, urinary, exercise is durable. | Standing recommendation for adult-male patients without contraindication. |
| BPC-157 / TB-500 | Voluminous animal data. Human data is small pilots (n=12–58). PCAC review July 23, 2026. | Indication-specific only — tendinopathy, joint injury with stalled rehab, IBD plateau. 4–8 week courses with reassessment. |
| Ipamorelin + CJC-1295 | Mechanism well-characterized. Long-term endpoint data is limited. | Selected patients seeking GH support; clear discussion of what the data does and does not support. |
| MOTS-c | Strong mechanistic case (AMPK / mitochondrial). Human trials are small. | Adjunct for metabolic and mitochondrial-fatigue presentations. |
| NAD+ therapy | NAD+ biology is well-established. Clinical-endpoint trials for IV/SubQ NAD+ are early. | Dr. Hare's personal recommendation. Loading IV protocol + SubQ maintenance with informed discussion. |
What the skeptics get right.
Topol's central point — and the one CNN echoes — is that the public conversation has gotten ahead of the trials. That is correct. The BPC-157 human dataset is genuinely small: a handful of pilot studies in interstitial cystitis, ulcerative colitis, and orthopedic case series, plus a recent IV-safety pilot in two healthy adults. CJC-1295/ipamorelin has mechanism and short-term GH response data; it does not have long-term healthspan or survival endpoints. The same is true for TB-500, MOTS-c, and most of the "wellness peptides" being marketed in 2026. Anyone telling you otherwise is either selling something or has not read the literature.
Topol is also right that the regulatory situation has been unstable. The April 23, 2026 reclassification restored legal compounding through licensed 503A pharmacies. The July 23–24 PCAC meeting will decide the durable shelf status. Patients deserve to know that the legal picture in October 2026 may differ from the picture today.
What the skeptics understate.
Two things. First: the preclinical record for BPC-157 is unusually consistent across species and injury models, with a clean adverse-event profile after two decades of study. For a compound being evaluated for inclusion on a compounding bulks list rather than for an NDA approval, that preclinical record is not a footnote — it is the substance of the regulatory case. Second: real-world clinical experience in sports medicine, regenerative medicine, and integrative gastroenterology now spans more than a decade. The published trials trail the lived practice. That is a known feature of compounded therapeutics, not a unique failure of peptides.
Tesamorelin and daily low-dose tadalafil are entirely outside the skeptic critique. Both are FDA-approved molecules with durable trial data. The Limitless tesamorelin position rests on a 2026 pooled meta-analysis. The daily tadalafil position rests on PDE5 inhibitor literature that the urology and cardiology communities have been building for twenty years. Calling these "peptide hype" is a category error.
The Limitless rules for prescribing inside thin evidence.
- No "feel-better" peptides. Every prescription is tied to a named clinical indication, not a vibe.
- 503A-pharmacy sourcing only. We audit our compounding partners on USP 797/795 compliance, COA reporting, and beyond-use dating. We are on track for two qualified partners on file by June 1, 2026.
- Defined courses with endpoints. 4–8 weeks for BPC-157/TB-500 with documented reassessment. No open-ended protocols.
- No oral BPC-157. Subcutaneous and intramuscular routes are better characterized. Oral preparations are not on our menu.
- Hard exclusions. Active or recent malignancy, pregnancy, and pre-existing contraindications are absolute. Documented in the chart.
- Honest informed consent. The patient gets the evidence tier in plain language before the prescription, not after.
What we don't prescribe.
We do not prescribe peptides that the literature does not support or that we cannot source through licensed 503A pharmacies. PT-141 is not on our default menu (selected use only, with documented indication). We do not currently use epitalon, GHK-Cu, or Semax outside of specific consult-only scenarios. We do not sell research-grade or imported product. We do not prescribe on a podcast-celebrity basis.
The bottom line.
The honest physician's response to the 2026 peptide skepticism is not to abandon the molecules — it is to tighten the prescribing. Stay inside the indications. Audit the source. Define the endpoint. Disclose the uncertainty. The patients who deserve these therapies are the ones we can write a clean, defensible chart note for. That is the Limitless standard, and it does not move when the news cycle does.